Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients

Abstract Background The DRCR.net Protocol T clinical trial assessed the comparative efficacy and safety of anti-VEGF treatments including aflibercept, ranibizumab and bevacizumab in diabetic macular edema (DME). Post -hoc analyses showed that after a 12-week induction period, there was still DME res...

Full description

Bibliographic Details
Published in:BMC Ophthalmology
Main Authors: J. M. Ruiz-Moreno, F. de Andrés-Nogales, I. Oyagüez
Format: Article
Language:English
Published: BMC 2020-09-01
Subjects:
Cost and cost analysis
Macular edema
Diabetic retinopathy
Aflibercept, Ranibizumab, Bevacizumab
Online Access:http://link.springer.com/article/10.1186/s12886-020-01637-0

Internet

http://link.springer.com/article/10.1186/s12886-020-01637-0

Similar Items